Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

The acquisition marks a turning point for the company after months of financial uncertainty and data breach concerns.

A Bay Area biotech company that laid off dozens of people this week has blamed the job cuts on policies of the Trump ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

The Beachwood-based company announced on Tuesday, May 20, that it has appointed Dr. David Llewellyn as its new CEO and as a ...

Commerce officials approved an incentives package worth up to $13.1 million for the company, which plans to build a $700 ...

Global private equity and venture capital investments in pharmaceutical companies lag 2024 figures, and regulatory headwinds ...